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Cells secrete around 30–1000 nm membrane-enclosed vesicles, of which members of
the subgroup between 30 and 100 nm are termed exosomes (EXs). EXs are released into
the extracellular space and are widely present in body fluids and incorporated mRNA,
miRNA, proteins, and signaling molecules. Increasing amounts of evidence suggest that
EXs play an important role not only in cell-to-cell communication but also in various
physiological and disease processes. EXs secreted by kidney cells control nephron
function and are involved in kidney diseases and cancers. This makes them potential
targets for diagnostic and therapeutic applications such as non-invasive biomarkers and
cell-free vaccines and for use as drug delivery vehicles. This review provides an overview
on the known roles of EXs in kidney development and diseases, including renal cancer.
Additionally, it covers recent findings on their significance as diagnostic markers and on
therapeutic applications to renal diseases and cancers. The intention is to promote an
awareness of how many questions still remain open but are certainly worth investigating.
Keywords: extracellular vesicles, exosomes, kidney development, diagnostic markers, therapeutics, renal
disease, renal cancer
INTRODUCTION
Cells from various organisms, including all the eukaryotes and many prokaryotes, release
extracellular vesicles of different types into their environment. The term exosomes (EXs) describes
those vesicles which are of endosomal origin. They are small (30–100 nm) membrane-enclosed
vesicles which are secreted by various cell types, and can be found in biological fluids such as blood,
semen, saliva, and urine (reviewed by Raposo and Stoorvogel, 2013; Yanez-Mo et al., 2015). Initially
these were considered to take part in the cell’s wastemanagement but evidence has accumulated that
they are instrumental in intercellular and system (humoral)-level communication in organisms.
The striking property of EXs is that they can transfer important compounds such as membrane
and cytosolic proteins, lipids, mRNA, miRNA (Valadi et al., 2007), and even DNA between cells.
Thus, they provide a novel but apparently evolutionary ancient platform for cell-to-cell and tissue
interactions (Valadi et al., 2007).
Even though the putative developmental role of EXs remains in most respects unclear, it is
emerging that at least many of the key developmental signaling pathways are coordinated by EXs
(Raposo and Stoorvogel, 2013; Urbanelli et al., 2013). Kidney cells, for instance, appear to release
vesicles presumably in a developmentally regulatedmanner, and the currently available data suggest
Krause et al. Exosomes as renal inductive signals
that EXs may initiate and regulate organogenesis. In addition,
they may also take part in processes such as regeneration and
the development of diseases such as cancer. Interestingly, kidney-
derived vesicles may also have an impact on the cells of certain
other organs (Grange et al., 2011) and even the immune system.
The aim of this review is to summarize the roles that have
been demonstrated for EXs in kidney development and disease,
especially in kidney tumorigenesis.
EXOSOMES AS RENAL INDUCTIVE
SIGNALS, DIAGNOSTIC MARKERS,
DISEASE, AND THERAPEUTIC AGENTS
Biogenesis and Signal Transduction
The biogenesis of EXs is a complex intracellular process that
forms part of the endosomal cell sorting machinery, in which an
array of regulatory factors has been identified (Stoorvogel et al.,
2002; Théry et al., 2002; Kowal et al., 2014). Upon the initiation of
EX assembly an early endosome is formed by an inward budding
of the cellular membranes via endocytosis. In association with
this budding the endosomal membrane undergoes a second
inward folding to generate further smaller vesicles inside the
endosomal lumen. The process is collectively called the formation
of multivesicular bodies (MVB; Figure 1).
FIGURE 1 | Biogenesis and uptake of exosomes. Inward budding of the membrane of an endosomal vesicle in the cytosol of the donor cell leads to the formation
of multivesicular bodies (MVBs). These can either turn into lysosomes, whereupon their content will be degraded, or fuse with the plasma membrane, releasing their
content into the extracellular environment. These vesicles are called exosomes. By contrast, larger microvesicles are formed when the cell membrane directly buds
outwards, giving rise to micelles. Exosomes can interact with recipient cells in various ways. Signaling can be initiated by an antigen-antibody interaction in the
recipient cell or by the activation of a receptor on the cell membrane of the target cell. Exosomes can also be taken up by endocytosis or fuse directly with the plasma
membrane. Upon fusion their cargo is released into the cytosol of the target cell.
The machinery known as the Endosomal Sorting Complex
Required for Transport (ESCRT) is involved in the formation
of MVBs, although it also entails an ESCRT-independent
mechanism involving proteins such as tetraspanins and lipids
(for details, see recent reviews by Hanson and Cashikar, 2012;
Henne et al., 2013; Colombo et al., 2014; Kowal et al., 2014). The
assembled MVBs can then fuse either with lysosomes, leading
to their degradation, or alternatively with the cellular plasma
membrane (PM), which releases their vesicles, called from here
on exosomes (EXs), into the extracellular milieu of the cell.
The fusion of MVBs with the PM was first described in the
hematopoietic system, namely in differentiating red blood cells
(Pan and Johnstone, 1983), and thereafter in several other cell
types such as B-cells, T-cells, dendritic cells (Escola et al., 1998;
Zitvogel et al., 1998; Blanchard et al., 2002), mast cells (Raposo
et al., 1997), and yeast cells (Henne et al., 2013). The biogenesis
of EXs has also been described in epithelial cells, including those
of the kidney (Knepper and Pisitkun, 2007), being the cells that
line the renal tubule lumen (Pisitkun et al., 2004).
On their release EXs interact with a recipient cell in several
ways. A schematic overview of the biogenesis of EXs and how
they enter target cells and interact with them is depicted in
Figure 1. As one mode of interaction, EXs bind to the target
cell via membrane receptors such as the Major histocompatibility
complex (MHC) that mediates binding to T-cells (Denzer et al.,
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2000; Nolte-’t Hoen et al., 2009). Another way in which EXs
bind is via recognition of the ligands on their lipid bilayer
by means of specific cell surface receptors. Indeed, many
common ligand/receptor pairs such as recognition by integrins
or tetraspanins have been identified. The capacity of an EX to
bind to a given cell depends to a great deal, however, on the
cellular content, and also the characteristics of the donor cell
from which the EXs originated. The most prominent binding
mechanisms have been reviewed recently by Colombo et al.
(2014) and are therefore, not reviewed here. Besides receptor-
mediated binding, the entry of EXs into a target cell may involve
endocytosis (Morelli et al., 2004), phagocytosis (Feng et al., 2010;
Christianson et al., 2013; Yanez-Mo et al., 2015), or pinocytosis
(Parolini et al., 2009; Théry et al., 2009; Yanez-Mo et al., 2015).
These processes can also be receptor-mediated, aided by several
other proteins such as dynamin (Fitzner et al., 2011) and clathrin
(Mulcahy et al., 2014; Tian et al., 2014), which regulate entry. In
the case of kidney-derived cells such as COS-7, the cells seem
to internalize EX through lipid raft-mediated endocytosis which
is negatively regulated by caveolin-1 (Svensson et al., 2013). It
is currently poorly understood whether EX uptake mechanisms
are common or specific to each cell type (Gildea et al., 2014).
Furthermore, there is also some debate as to how widely certain
EXs can influence cell behavior (White et al., 2006; Svensson et al.,
2013).
Exosomes in Kidney Physiology
The currently available data suggest that the extracellular vesicles
are coupled to normal development and various diseases. Given
that EXs contain key regulatory signals such as mRNA and
miRNA and can transfer them from one cell type to another,
they may have a profound influence on target cell homeostasis
(Montecalvo et al., 2012; Stoorvogel, 2012; Tomasoni et al., 2012;
Zhang et al., 2015b). The capacity of EXs to transport miRNA
is of particular importance when considering participation in
developmental control in general (Tang et al., 2007). Even though
it still remains unknown whether EXs indeed play a crucial
role in morphogenesis, the current results suggest that at least
urinary EXs, besides being involved in the secretion of senescent
proteins as exocytic waste (Pisitkun et al., 2004; Knepper and
Pisitkun, 2007) may also have other roles (van Balkom et al.,
2011; Fang et al., 2013). In the light of current data, the systemic
serum containing EXs cannot cross the kidney filter within the
glomerulus under normal conditions (Pisitkun et al., 2004; Gildea
et al., 2014), but whether this changes in the presence of kidney
anomalies remains open.
Proteomic studies of urinary EXs have identified proteins that
characterize certain nephron segments such as the glomerulus
and Henle’s loop. A summary is given in Table 1 (Pisitkun
et al., 2004; Miranda et al., 2010; Dear et al., 2013). The
available data suggest that most, if not all, of the nephron cell
types have the capacity to secrete vesicles. EXs may play an
important role in mediating cell-to-cell communication along
the nephron with potential significance for kidney performance,
and it has been shown that the function of the EXs within
the nephron may be the adaptation of nephron function to
changes in physiology, i.e., in homeostasis. This possibility is
based on the observation that different segments of the nephron
secrete and take up EXs differentially (Dimov et al., 2009). Renal
EXs can also transfer functional molecules such as aquaporin-2
between cells (Street et al., 2011), although their uptake capacity
becomes restricted in the fully matured adult kidney. This is
probably caused by accumulation of the tubular Tamm-Horsfall
protein, which prevents contacts between EXs and the tubular
luminal cells unless this protein is degraded locally (van Balkom
et al., 2011). Hence, the luminal epithelial cells of the nephron
apparently secrete the EXs found in urine. Furthermore, proteins
which are specifically associated with the urinary bladder and
prostate gland have also been found in urine (Musante et al.,
2014), although further studies are needed to provide conclusive
evidence of this.
When considering the embryonic kidney and the potential of
EXs for taking part in its developmental programming, many of
the proteins known to control organogenesis, including growth
factors (see the recent review by Krause et al., 2015) are in fact
found in the EXs that have been characterized from a variety of
cell lines (Table 2). The Wnt-family members and their signal
transduction pathway are critical for kidney development, and
interestingly, several Wnt proteins and their downstream factors
such as β-catenin are associated with EXs and can also mediate
activation of the pathway (Table 2; Zhang et al., 2015a). It can be
speculated that a panel of key developmental signals may also be
associated with and transported to the target cells via EXs during
kidney development.
If this is the case, then EXs constitute a new critical mechanism
in the control of kidney development by transferring and
integrating key inductive signals. Thus, their presence during
kidney development should be explored further: Which cells
secrete EXs under which environmental conditions, and do these
EXs populations differ one from another? Further analysis should
then reveal details of their content, transport mechanisms and
physiological roles during kidney development.
The putative role of EXs has recently been explored in Madin-
Darby canine kidney cells (MDCK; Kwon et al., 2014). When
these cells are subjected to the hepatocyte growth factor (HGF)
their proliferation is stimulated and eventually tubular cysts
form. Changes in the expression of a specific G protein-coupled
receptor, GPRC5B, are associated with EXs being secreted by
these cells. This protein is also up-regulated in tubulogenesis,
while the exosomal delivery of GPRC5B induces extracellular
signal-regulated kinase 1/2 (Erk1/2). As the GPRC5B is expressed
in the ureteric bud of the embryonic kidney, this may suggest that
it also plays a role in organogenesis.
The Role of Exosomes in Kidney
Regeneration and Diseases
While the role of kidney-derived EXs in physiological processes
remains poorly investigated, EXs have been found to exercise
beneficial or adverse functions in the development of several
kidney diseases (Borges et al., 2013a; Fang et al., 2013). For
example, vesicles derived frommesenchyme stem cells (MSCs) or
endothelial stem cells can promote kidney regeneration (Borges
et al., 2013a). The positive impact of MSCs on both acute and
chronic kidney injury (AKI and CKI) was first attributed to
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TABLE 1 | Proteins found in human urinary exosomes that are specific to or enriched in given regions of the kidney.
Kidney region Gene symbol Full gene name Species Exosome
sample
Identified
molecule
Associated diseases
Glomerulus PODXL Podocalyxin-like Protein Homo sapiens Urine Protein Diabetic nephropathy
NPHS2 Podocin Homo sapiens Urine mRNA Focal segmental glomerulosclerosis,
nephrotic syndrome [MIM: 600995]
LGALS1 Galectin-1 Homo sapiens Urine mRNA –
HSPG2 Heparan Sulfate Proteoglycan 2 Homo sapiens Urine mRNA Schwartz-Jampel syndrome type 1
[MIM: 255800]
1st convoluted
tubule
gp330 precursor Glycoprotein 330 Precursor Homo sapiens Urine Protein Renal aminoglycoside accumulation
and nephrotoxicity, Donnai-Barrow
syndrome
CUBN Cubilin (Intrinsic
Factor-Cobalamin Receptor)
Homo sapiens Urine Protein,
mRNA
Megaloblastic anemia 1 [MIM:
261100]
AQP1 Aquaporin1 Homo sapiens Urine protein,
mRNA
Nephrogenic diabetes insipidus,
Aquaporin 1 deficiency, Colton-Null
[MIM: 110450]
LRP2 Megalin Homo sapiens Urine mRNA Heymann nephritis, proteinuria
CA4 Carbonic Anhydrase 4 Homo sapiens Urine mRNA Diabetic nephropathy, Proximal renal
tubular acidosis [MIM: 114760]
ANPEP Alanyl Aminopeptidase Homo sapiens Urine protein Hypertension [MIM: 151530]
NAPSA NapsinA Homo sapiens Urine Protein Kidney carcinoma, renal neoplasms
CLCN 5 Chloride Channel Protein 5 Homo sapiens Urine mRNA Dent’s disease
GGT1 γ-glutamyltransferase Homo sapiens (male) Urine Protein –
APN Aminopeptidase N Homo sapiens (male) Urine Protein –
Henle’s loop AQP1 Aquaporin 1 Homo sapiens Urine Protein Nephrogenic diabetes insipidus,
Aquaporin 1 deficiency, Colton-Null
[MIM: 110450]
UMOD Uromodulin Homo sapiens Urine Protein Hyperuricemic nephropathy,
Medullary cystic kidney disease-2
(MCKD2) [MIM: 603860], familial
juvenile hyperuricemic nephropathy
(FJHN) [MIM: 16200]
THP Tamm-Horsfall Protein Homo sapiens (male) Urine Protein Mckd2 [mim: 603860], fjhn [mim:
16200]
CD9 Cluster of Differentiation
(Tetraspanin)
Homo sapiens (male) Urine Protein –
BDKRB1 Bradykinin B1 Receptor Homo sapiens Urine mRNA –
CALCR Calcitonin Receptor Homo sapiens Urine mRNA Kidney stone disease
SCNN1D Amiloride-sensitive Sodium
Channel Subunit Delta
Homo sapiens Urine mRNA –
2nd convoluted
tubule
SLC12A3 (NCC) Thiazide-sensitive Na-Cl
Cotransporter
Homo sapiens Urine Protein Gitelman syndrome [MIM: 263800]
Collecting ducts AQP2 Aquaporin 2 Homo sapiens Urine mRNA Nephrogenic diabetes insipidus type
1 [MIM: 222000] [MIM: 125800]
ATP6V1B1 V-ATPase B1 Subunit Homo sapiens Urine mRNA Distal renal tubular acidosis [MIM:
267300]
SLC12A1 Kidney-specific Na-K-Cl
Symporter
Homo sapiens Urine mRNA Bartter-Syndrome type 1, 2, 3 [MIM:
601678, 241200, 607364]
MUC1 Mucin-1 Homo sapiens (male) Urine Protein Renal cell carcinoma, Medullary cystic
kidney disease type 1 (MCKD1)
[MIM:174000]
RHCG Rh type C glycoprotein Homo sapiens (male) Urine Protein –
Data compiled from Pisitkun et al. (2004), Gonzales et al. (2009), Miranda et al. (2010), Dear et al. (2013), and Musante et al. (2014) and the Online Mendelian. Inheritance in Man
OMIM® website (http://www.omim.org/, see MIM numbers for reference).
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TABLE 2 | Genes of importance during kidney development found in exosomes of various origins.
Gene
symbol
Full gene name Species Exosome sample Identified
molecule
References ExoCarta ID
(Mathivanan and
Simpson, 2009)
Wnt4 Wingless-type MMTV Integration
Site Family, Member 4
Homo sapiens Umbelical cord
mesenchymal stem
cells
protein Zhang et al., 2015a No
Wnt11 Wingless-type MMTV Integration
Site Family, Member 11
Mus musculus Mast cells mRNA Valadi et al., 2007 ExoCarta_22411
Notch2 Neurogenic locus notch homolog
protein 2
Homo sapiens Ovarian cancer cells Protein Liang et al., 2013 ExoCarta_4853
Homo sapiens Colorectal cancer cells Protein Demory Beckler et al., 2013 ExoCarta_4853
Bos taurus Milk Protein Reinhardt et al., 2013 ExoCarta_513730
BMP4 Bone Morphogenetic Protein 4 Homo sapiens Colorectal cancer cells Protein Demory Beckler et al., 2013 ExoCarta_652
FGFR1 Fibroblast Growth Factor receptor 1 Homo sapiens Ovarian cancer cells Protein Liang et al., 2013 ExoCarta_2260
OSR1 Oxidative Stress responsive 1 Homo sapiens Ovarian cancer cells Protein Liang et al., 2013 ExoCarta_9943
Homo sapiens Thymus Protein Skogberg et al., 2013 No
Homo sapiens Urine Protein Gonzales et al., 2009 No
Rattus norwegicus Reticulocytes Protein Carayon et al., 2011 ExoCarta_316064
WT1 Wilms Tumor 1 Homolog Mus musculus Mast cells mRNA Valadi et al., 2007 ExoCarta_22431
Ranghino et al., 2014 No
β-catenin Cadherin-associated protein beta Mus musculus Dendritic cells Protein Chairoungdua et al., 2010 No
their role in directly replacing renal tubular cells, but later it
became clear that these cells rather provide paracrine support for
endogenous regeneration (Biancone et al., 2012). At present the
role of MSCs has been assigned in part to the secretion of EXs
(Camussi et al., 2010; Biancone et al., 2012; Borges et al., 2013a),
e.g., in that MSC-derived EXs can enhance regeneration of the rat
kidney epithelium when injured by ischemia-reperfusion (Gatti
et al., 2011). This EX-mediated recovery involves cell-to-cell
transfer of mRNAs and/or microRNAs and may be connected
with the inhibition of renal cell apoptosis and the stimulation
of tubular epithelial cell proliferation. Moreover, by reducing
the acute injury, the EXs also protected the rats from later CKI
development 6 months after the operation (Gatti et al., 2011).
Other studies have reported a regenerative potential in
microvesicles (MVs) produced by bone marrow MSCs in
glycerol-induced (Bruno et al., 2009), cisplatin-induced (Bruno
et al., 2012), and gentamicin-induced (Reis et al., 2012) AKI
models via a mechanism dependent on RNA delivery. Here
the protective effect of EXs was mainly ascribed to an increase
in surviving tubular cell proliferation (Bruno et al., 2009; Reis
et al., 2012) and a decrease in tubular epithelial cell apoptosis
(Bruno et al., 2009, 2012; Reis et al., 2012). These effects are
thought to occur via the up-regulation of anti-apoptotic genes
and down-regulation of genes involved in the execution phase of
cell apoptosis (Bruno et al., 2012).
It has also been found that the development of chronic tubular
injury is inhibited by multiple injections of MVs, while the
effect of a single injection was not sufficient to prevent CKI
(Bruno et al., 2012). Like bonemarrowMSC-derived EXs, human
umbilical cord MSC-derived EXs also demonstrated a protective
effect on cisplatin-induced nephrotoxicity in vivo and in vitro,
whereas human lung fibroblast-derived EXs did not (Dorronsoro
and Robbins, 2013; Zhou et al., 2013a). Zhou et al. (2013a)
demonstrated that these EXs can reduce cisplatin-mediated renal
oxidative stress and apoptosis in rats in vivo and increase the
proliferation of renal tubular epithelial NRK-52E cells in culture.
They also showed that human umbilical cord MSC-derived EXs
can reduce Bax (bcl-2-like protein 4) level and increase Bcl-2
(B-cell lymphoma 2) in order to inhibit apoptosis and stimulate
Erk1/2, thereby increasing proliferation after cisplatin-induced
injury in the kidney. Another group has shown that EXs isolated
from peripheral blood-derived endothelial progenitor cells can
prevent AKI in an ischemia-reperfusion rat model (Cantaluppi
et al., 2012). In this case the miRNAs that modulate proliferation,
angiogenesis and apoptosis were found to be responsible for the
protective effects of EXs.
Kidney epithelial cells are another source of the EXs involved
in kidney regeneration. It was found that administration of
the epithelium-derived exosomal ATF3 (activating transcription
factor 3) mRNA attenuates ischemia/reperfusion-induced kidney
injury by inhibiting monocyte chemotactic protein-1 (MCP-1)-
induced macrophage infiltration (Chen et al., 2014b). While all
the above-mentioned studies demonstrate beneficial effects of
EXs on kidney regeneration, it was found on the other hand that
EXs produced by injured proximal tubular epithelial cells in a
murine model of hypoxic kidney fibrosis after unilateral ureteral
obstruction can initiate tissue repair/regenerative responses
and activate fibroblasts, leading to fibrosis (Borges et al.,
2013b). Fibroblast proliferation and the production of matrix
proteins were particularly dependent on EXs delivering TGF-β1
(transforming growth factor β1) mRNA (Borges et al., 2013b).
Interestingly, certain in vitro studies published more than 20
years ago demonstrated that renal brush border-derived MVs
about 100 nm in diameter can induce and promote calcium
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oxalate crystallization (Nagasawa et al., 1992; Anderson et al.,
2010), which is one of the features of nephrolithiasis (kidney
stone formation), a pathological kidney condition leading to
fibrosis and chronic renal failure (Anderson et al., 2010).
Since, the endothelial cells are connected to the control of
blood flow, pressure and clotting, they are prime targets when
considering the development of EX-based therapies, and also
the treating of renal diseases (van Balkom et al., 2011). It
has been shown that circulating levels of endothelial-derived
MVs are significantly higher in chronic renal failure patients
than in healthy subjects (Faure et al., 2006). Moreover, blood
levels of these MVs correlate with endothelial dysfunction and
arterial stiffness in end-stage renal failure hemodialysis patients
(Amabile et al., 2005). In contrast to endothelium-derived MVs,
those produced by platelets or erythrocytes do not seem to be
connected with endothelial dysfunction (Amabile et al., 2005).
In another study it was found that the number of endothelial-
derived microparticles was inversely correlated with brachial
artery and aortic laminar shear stress values in end-stage renal
disease patients with a high cardiovascular risk (Boulanger et al.,
2007).
It may be assumed that the action of cell-damaging agents
such as low shear stress and increased arterial stiffness
contributes to endothelial apoptosis through a substantial release
of endothelial MVs (Amabile et al., 2005; Boulanger et al.,
2007). The pathogenetic effects of EXs and other circulating
microparticles in promoting vascular calcification and sclerosis
in chronic kidney disease (CKD) are nevertheless not yet
clearly defined (Anderson et al., 2010; Fang et al., 2013).
Rather surprisingly, Neal et al. (2011) found that the levels of
circulating miRNAs in patients with different stages of chronic
kidney failure, including those receiving hemodialysis treatment,
were reduced by comparison with patients having mild renal
impairment or normal renal function. This observation might be
explained by the fact that many circulating miRNAs are bound
to Argonaute 2-containing protein complexes (Arroyo et al.,
2011) or to high-density lipoproteins (Vickers et al., 2011) rather
than within EXs. It has been demonstrated in a rat model of
CKD induced by 5/6 nephrectomy that the administration of
conditioned medium from embryonic MSC has a therapeutic
effect, whereasMSC-derived EXs tested in the same experimental
setting showed no protective effect on the kidney (van Koppen
et al., 2012).
Exosomes in Kidney Cancer
Although tumor cells secret large amounts of various MVs that
enter the blood and other body fluids (Lee et al., 2011; Azmi
et al., 2013), the isolation of cancer EXs from patients remains
a serious problem due to the lack of specific markers that
can distinguish cancer-derived from non-cancer-derived EXs.
One such marker that has been identified recently is glypican-
1, detected on EXs derived from the serum of patients with
pancreatic cancer but not on EXs from healthy subjects or
subjects with chronic pancreatitis (Melo et al., 2015). Various
biological roles have been proposed for EXs in cancer, such
as the expulsion of key proteins and miRNA from cells, the
removal of anti-cancer drugs and the release of signaling and
regulatory molecules (Lee et al., 2011; Azmi et al., 2013).
The properties of EXs may also enable them to take part
in the control of cell proliferation, cell survival, angiogenesis,
metastasis and immune response (Azmi et al., 2013; Fang
et al., 2013). EX-released factors promote stromal remodeling
and hypoxia-mediated epithelial mesenchyme transformation,
which is critical for the evolution of cancer (Nieto, 2011). EXs
can also stimulate the proliferation of fibroblasts by causing
a desmoplastic reaction, and they can induce immune escape
mechanisms by suppressing antigen-specific immune responses
and by up-regulating immunosuppressive cell differentiation and
the functioning of these cells (Azmi et al., 2013; Minciacchi
et al., 2015). For these reasons EXs form a critical aspect of
tumorigenesis.
Much less is known at present about the roles of EXs in
kidney tumorigenesis, however. The relevant findings are that
the vesicles released by renal carcinoma stem cells (rCSCs)
derived from a tumor-bearing patient can trigger angiogenesis
and promote lung metastasis when studied with the SCID
(immunocompromised severe combined immunodeficient)
mouse model (Grange et al., 2011). Grange et al. (2011) showed
that rCSCs are secreted by a subset of tumor-initiating cells
characteristically expressing the mesenchymal stem cell marker
CD105, and that EXs derived from these rCSCs were able
to stimulate the growth and invasiveness of normal HUVEC
(human umbilical vein endothelial cells). In addition, these EXs
increased the formation of capillary-like structures in culture
and in induced vessel formation when cells treated with them
were grafted into SCID mice.
More detailed molecular characterization of the CD105-
positive EXs pointed to significant differences in mRNA and
miRNA content as compared with EXs that were negative
for CD105. Consistent with their properties, the rCSC-derived
EXs have mRNAs that encode for proangiogenic factors
such as vascular endothelial growth factor (VEGF), fibroblast
growth factor (FGF), angiopoietin-1, ephrin A3, and matrix
metalloproteinases (MMP)-2 and -9. Similarly, these were
reported to be absent from the CD105-negative tumor cell-
derived EXs. In addition to these findings, miRNAs that have
been reported to be involved in biological processes such as
the control of transcription, cell adhesion and cell proliferation
were enriched in CD105-positive EXs (Grange et al., 2011,
2014).
Another indication that EXs derived from kidney cancer
cells may be involved in the cancerous state and its severity,
including the formation of metastases, came from the work of
Tauro et al. (2013), who performed a proteomic analysis by
comparing EXs released by normal and oncogenic H-Ras (21D1)
transfected MDCK cells. While the control and 21D1-MDCK
cell-derived EXs were similar in their morphology, the 21D1-
derived EXs had high levels of proteases, annexins, integrins, and
other secreted proteins which are typically associated with the
formation of premetastatic niches. The ability of primary cancer
to make changes in normal tissue located in a pre-metastatic
niche prior to the arrival of metastasizing cells is an important
feature that facilitates sustained cancer growth (Wels et al.,
2008).
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The role of EXs in the “education” of normal cells toward
a pro-metastatic phenotype has been demonstrated not only
for renal cell carcinoma but also for other cancers, including
melanomas (Peinado et al., 2012) and breast cancer (Fong
et al., 2015). Elsewhere, the transfection of MDCK cells with
oncogenic H-Ras has been found to induce the release of EXs that
contain factors known to control nuclear assembly, transcription,
splicing, and translation. The most abundant protein in the
21D1-derived EXs was the Y-box-binding protein (YBX1), which
is a DNA andRNA- binding transcription factor involved inDNA
replication, DNA repair, transcription, pre-mRNA splicing, and
mRNA translation (Eliseeva et al., 2011).
Several studies have been conducted employing 786-0 human
renal adenocarcinoma cells and targeted EXs in carcinogenesis
(Zhang et al., 2013; Chen et al., 2014a; Du et al., 2014). Like
the rCSC-derived EXs (Grange et al., 2011) the 786-0-derived
ones promote tubulogenesis in HUVECs (Human umbilical
vein endothelial cells; Zhang et al., 2013), and it has been
speculated that the pro-angiogenic effect of these renal EXs may
be mediated via down-regulation of hepaCAM (hepatic and glial
cell adhesion molecule), a hepatocyte cell adhesion molecule, and
up-regulation of VEGF. In turn, it has been shown that the EX-
mediated down-regulation of hepaCAM expression is in effect
mediated by Akt phosphorylation connected with the enhanced
renal carcinoma cell proliferation (Jiang et al., 2014). Collectively,
the 786-0-derived EXs enhance cell migration, invasion and
chemokine receptor type 4 (CXCR4) and MMP-9 expression and
concurrently reduce the adhesion of 786-0 cells (Chen et al.,
2014a).
A comprehensive report on the influence of EXs on renal
carcinoma 786-0 cells has been published recently by Du et al.
(2014), who investigated the putative effects of EXs released by
human Wharton’s jelly mesenchyme stem cells (hWJ-MSCs).
These EXs promoted cell proliferation, cell migration, and
progression of the cell cycle from G0/G1 to the S phase and the
HGF/c-Met, Akt, and Erk1/2 pathways in these cells. Moreover,
the hWJ-MSCs-derived EXs stimulated tumorigenesis in the 786-
0-cells and also enhanced tumor size. At the molecular level, the
EXs induced cyclin D1, MMP-2, and MMP-9 expression in a
BALB/c nude mouse model (Du et al., 2014). Meanwhile, RNase
pre-treatment abrogated these exosomal effects, indicating that
the RNA delivered via EXs serves as a crucial mediator (Du et al.,
2014).
Little is known as to whether the cells in various organs
take up the cancer-derived EXs selectively. Rana et al. (2012)
found that small differences in the EX-tetraspanin complexes that
originated from different rat tumor cell lines greatly influenced
the cell type to which the EXs were targeted in vitro or in vivo.
When tetraspanin-8+ EXs were monitored after 24 h of injection
they had been taken up by the pancreas and lung cells, whereas
certain large vessels and the kidneys showed a lower abundance
of such EXs. Moreover, the liver and gut cells were for the most
part negative. These data thus suggest some target cell selectivity
among EXs that are secreted in vivo.
Interestingly, EXs engineered to express a chimeric
tetraspanin-8 in which the N-terminal region was swapped for a
domain from the CD9 protein were readily taken-up by kidney
cells but not by other organs, whereas EXs engineered to contain
tetraspanin-8 that was fused to an integrin β4 was targeted
preferentially to lung, kidney and gut cells. It is significant that
also within an organ, EXs seem to be taken up preferentially by
specific cell types depending on the exosomal protein content.
One indication of this is the fact that tetraspanin-8; integrin
β+ fusion EX products could be identified in only the kidney
glomeruli (Rana et al., 2012).
There are several reports stating that EXs produced by
kidney tumor cells are coupled to cancer-associated immune
suppression (Yang et al., 2013; Diao et al., 2015; Gu et al.,
2015). As an example of this, EXs purified from human
kidney adenocarcinoma ACHN cells inhibited proliferation
and induced apoptosis of Jurkat-immortalized T-cells while
reducing in vitro interleukin-2 (IL-2), IL-6, IL-10 and interferon-
γ production (Yang et al., 2013). In the light of these findings,
the authors proposed that the Fas ligand within the tumor-
derived EXs must be responsible for exosomally induced T-cell
death.
There is considerable evidence that EXs play a role in renal
tumor progression in vivo. The survival of mice inoculated with
renal adenocarcinoma Renca cells, which go on to generate
tumors, was reduced to some degree in the presence of Renca-
derived EXs in the assay (Gu et al., 2015), and similar data
have been reported by Diao et al. (2015), leading them to
propose that the heat shock protein HSP70 present in EXs
derived from cancer cells promotes the immunosuppressive
activity of myeloid-derived suppressor cells (MDSCs), possibly
via an increase in Stat3, a signal transducer and activator of
transcription 3-phosphorylation.
Besides suppressing the immune system, EXs can also
do exactly the opposite. Certain tumor-derived EXs induce
an immune response. This suggests that EXs may even
offer opportunities for developing individualized tumor
immunotherapies (Greening et al., 2015). Given the fact that
tumor-derived EXs also contain immunosuppressive molecules
that reduce their immunogenicity, it is important to learn
in detail how these properties are regulated, opening new
avenues for valuable therapeutics. Along these lines, EXs that
are secreted by IL-12-expressing RC-2 human renal cancer cells
exhibited greater anti-tumor effects than EXs derived from “wild
type” renal cells or cytocine-supplemented IL-12 alone (Zhang
et al., 2010). Such IL-12-containing EXs efficiently induced
cell proliferation, the release of interferon-gamma and the
specific cytotoxic effects of T-cells derived from cultured human
peripheral blood cells.
It is also of interest that the mice that had tumors derived
either from the mouse myeloid leukemia line WEHI3B or
renal carcinoma Renca cells survived longer if they had been
vaccinated beforehand with the EX-loaded dendritic cells from
the tumor (Gu et al., 2015). In other words, the tumor cell-derived
EXs seemed to be superior to the tumor lysates as a source of
antigen. Interestingly, the immunosuppressive features of EXs do
not detract from their capacity to serve as an antigen source for
the dendritic cells (Gu et al., 2015). These properties make the
EXs very promising components for the development of novel
cancer therapies.
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Kidney/Urinary Exosomes as Diagnostic
Biomarkers and Therapeutic Agents
EXs have a great potential for use as valuable diagnostic
biomarkers, especially in the case of monitoring kidney
malfunction. Since, many reviews have been published on the
analysis of urinary EXs and their potential as diagnostic markers
for kidney disease, injury, and transplant rejection, this topic
will be covered in the present review only briefly (Knepper and
Pisitkun, 2007; Dimov et al., 2009; Dear et al., 2013; Properzi
et al., 2013; Musante et al., 2014; Ranghino et al., 2014; Salih et al.,
2014).
As discussed, the urinary EX components can be assigned to
specific nephron segments, the glomerulus, the proximal/distal
tubule, Henle’s loop and the collecting duct (Table 1; Pisitkun
et al., 2004; Miranda et al., 2010; Dear et al., 2013; Musante et al.,
2014). Many of these proteins can be associated with certain
diseases, but they are not all necessarily linked directly to the
kidney. The level of GPRC5B in the urinary EXs correlates with
AKI, so that its values are elevated in cases of AKI by comparison
with normal healthy subjects (Kwon et al., 2014), making
GPRC5B a candidate diagnostic marker for AKI. Furthermore,
levels of Fetuin-A were also found to be elevated in patients
suffering from AKI (Zhou et al., 2006).
The review by Ranghino et al. (2014) summarizes several
suitable urinary exosomal biomarkers for glomerular and tubular
damage, including Wilms Tumor 1 Homolog (WT1), ATF3, and
Neutrophil Gelatinase-Associated Lipocalin (NGAL). WT1 was
found in urinary exosomes of patients who suffer from focal
segmental glomerulosclerosis (FSGS; Zhou et al., 2008, 2013b)
and inmost diabetic patients (Kalani et al., 2013). ATF3 is another
marker for AKI alongside Fetuin A and GPRC5B (Zhou et al.,
2008). NGAL levels were elevated in patients with delayed graft
function after kidney transplantation (Alvarez et al., 2013), and
several protein markers have also been found in cases of diabetic
nephropathy (Zubiri et al., 2014) and prostate (Lu et al., 2009;
Mitchell et al., 2009) and urine bladder cancer (Smalley et al.,
2008; Blackwell et al., 2014).
Some markers that classify a person as healthy have also
been identified, and these may be of diagnostic value in cases
of kidney regeneration. Promonin-1 (CD133) serves as such
a marker, for example, as it is lost in the urine at the end
stage of renal disease (Dimuccio et al., 2014), and additional
markers have been defined for a panel of kidney diseases that
include diabetic nephropathy (Musante et al., 2014), cardio-renal
syndrome (Gonzalez-Calero et al., 2014), autosomal-dominant
polycystic kidney disease (ADPKD; Fang et al., 2013; Ben-Dov
et al., 2014) and Gitelman’s and Bartter syndromes (Corbetta
et al., 2015), as well as for following the organ-acceptance after
a kidney transplantation (Alvarez et al., 2013).
In 2007 the group led by Jan Löttvall found that EXs carry
different functional RNA species (Valadi et al., 2007). Renal
mRNA levels have been used in the past as prognostic markers
for kidney diseases (Eikmans et al., 2003), but this required an
invasive kidney biopsy. Analysis of the protein and RNA content
of urinary EXs provides a non-invasive alternative for evaluating
changes in renal gene and protein expression, and it has been
found that several exosomal microRNAs isolated from urine are
suitable markers for certain kidney diseases. One study showed
that exosomal miR-145 and miR-130a levels were elevated in
patients with diabetic nephropathy, while levels of miR-155 and
miR-424 were down-regulated (Barutta et al., 2013). Further
studies with a larger group of patients would be necessary to
confirm these results.
Several miRNA markers of CKD/renal fibrosis have been
identified. Levels of exosomal miR-29a, miR-29c, miR-200b, and
miR-200c were down-regulated in patients with moderate-to-
severe fibrosis (Lv et al., 2013), but not in cases with mild
fibrosis. The same paper also demonstrates that miR-29c provides
indicators of renal function and the histological degree of fibrosis,
making it the most prominent candidate for a biomarker of CKD,
while (Lv et al., 2014) showed that the exosomal mRNA level of
CD2-associated protein (CD2AP) was down-regulated in CKD
patients, and even more so in patients with a more severe disease.
Both of these reports not only identified disease markers, but also
demonstrated that the level of miRNA/mRNA present in urinary
EXs provides an opportunity to define the progression of the
disease.
Protocols for analyzing exosomes and isolating RNA from
them still have to be optimized further in order to yield unbiased,
reliable results. Furthermore, it still needs to be ascertained
whether levels of exosomal mRNA can also reflect levels of
the proteins used as biomarkers for kidney diseases. The same
RNA and protein markers as were used in the past when a
kidney biopsy was performed might not apply to exosomal
RNA and protein levels, as is supported by the fact that little
equivalence was found between the exosomal and cellular RNAs
of exosome-producing cells (Skog et al., 2008; Mittelbrunn et al.,
2011; Koppers-Lalic et al., 2014). This implies an underlying
mechanism for the targeted loading of certain RNA species into
EXs, in contrast to the loading of the most abundant cellular
RNA into EXs in order to discard it. Future studies will have
to elucidate the sorting mechanisms responsible for this process.
Nonetheless, it is this fact that makes EXs especially interesting,
as mRNAs and miRNAs can influence gene expression in the
recipient cell and providing the EXs with their therapeutic
potential.
One therapeutic strategy would be that RNA-bearing EXs
would deliver their cargo to specific malfunctioning target cells
and could restore damaged or deregulated protein production.
Several studies have shown that exosomes shuttle functional
miRNA and influence the gene expression levels of target cells
(Pegtel et al., 2010; Montecalvo et al., 2012; Chen et al., 2014c).
Another promising feature of EXs is to serve as a non-
cytotoxic drug delivery system. The challenge still lies in loading
the drugs onto the EXs without imperiling their biological
properties (Suntres et al., 2013). Different methods for loading
a defined cargo onto EXs have been established, as recently
reviewed (Johnsen et al., 2014). This is a possible way of
developing novel therapeutics to treat various diseases. Some
examples exist of studies which are currently in clinical trial
phase I.
One such investigation concerns the potential application of
EXs to deliver curcumin (which has proved to have biological
activity) to colon cancer tissue (clinical trial no. NCT01294072),
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while another uses EXs as a vaccine, administering dendritic cell-
derived EXs (CSET 1437) loaded with antigen to lung cancer
patients in order to activate their innate and adaptive immunity
during therapy (clinical trial no. NCT01159288). Furthermore,
the potential application of EXs to the treatment of kidney
diseases is being explored. As described in Section The Role of
Exosomes in Kidney Regeneration and Diseases above, various
groups have shown that MSCs have a paracrine effect on acute
and chronic kidney diseases (Gatti et al., 2011; van Balkom
et al., 2011; Fang et al., 2013) in which soluble factors such
as those associated with the secreted vesicles have a positive
influence on cell behavior and promote the initiation of recovery.
The potential of EXs for use in cell-free therapy applications
has been summarized recently (Vishnubhatla et al., 2014) and
will not be discussed here in detail. It is clear, however, that
EXs from various cells such as MSCs and cancer cells have
a great potential as novel therapeutic tools, and they can be
expected to have a significant impact on the development of
diagnostics and new treatments, for kidney diseases among
others.
CONCLUSIONS
It has become generally accepted for the moment that EXs
are present in a wealth of body fluids and are not only
a cellular waste system as was thought earlier. Collectively,
they may represent a newly identified but apparently ancient
humoral system controlling homeostasis and disease, and they
also provide a useful bank of biomarkers for a variety of diseases
and may raise the value of urine as a non-invasive diagnostic
component in medical practice. The analysis of urinary EXs not
only provides us with prognostic disease markers, but might also
make it possible to differentiate between diseases which display
similar symptoms. Furthermore, certain data have shown that
it is possible to estimate the severity of a disease, and hence
its progression. This could enable non-invasive monitoring of
responses to treatment and also make it possible to look for
complications after kidney transplantations. The use of EXs
as therapeutics and vaccines seems to be safe and effective
due to their target specificity and their lack of cytotoxicity.
This and the fact that a specific cargo can be loaded into
them also make them very promising candidates as novel drug
delivery systems. This is still something of a challenge, however,
and better protocols need to be developed. More research will
be necessary to ensure the safety of the resulting medical
applications.
A schematic overview of the signaling role of EXs in relation
to the kidney is presented in Figure 2. It is known that EXs play a
role in kidney diseases and renal cancer, butmany of the signaling
molecules found during nephrogenesis occur in association with
EXs, leading us to conclude that they not only participate in
disease processes but also play a putative role in developmental
processes. Which machinery regulates these processes during
embryonic kidney development still remains largely an open
FIGURE 2 | Exosome-mediated signaling during kidney development, disease, and cancer. The signaling is symbolized by a thin gray arrow, while the
development from one cell type/cell state to another is symbolized with a larger arrow. Different types of embryonic kidney cells release vesicles (small circles) to
transfer signals during morphogenesis. These initiate and regulate the development of the organ. Exosomes are a means of cell-to-cell communication. When
abnormal kidney conditions appear, exosomes can be released from the abnormal cells to be subsequently taken up by healthy cells, which will then be transformed
and might even become abnormal as well. It has been reported that exosomes released from transformed kidney cells can initiate cancer in lung cells (Grange et al.,
2011; Rana et al., 2012) and lead to tumor-promoted immune suppression in certain immune cells (Yang et al., 2013; Diao et al., 2015; Gu et al., 2015). Kidney cells
and transformed kidney cells also take up the released vesicles again (dotted lined arrows). Most of the means of signaling depicted here are still not very
well-characterized or understood.
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question, but the accumulating evidence is starting to point
toward a critical role for EXs in inductive signaling in the kidney.
Future work should be targeted toward elucidating the normal
physiological roles of EXs in vivo in defined disease models and
advancing our knowledge of the precise mechanisms by which
they promote renal diseases and cancer.
AUTHOR CONTRIBUTIONS
MK drafted the manuscript and prepared the figures and tables.
AS helped with writing the manuscript and designing the figures.
AS and SV critically reviewed and revised the manuscript.
All three authors read and approved final version of the
manuscript.
FUNDING
This work was supported by the Academy of Finland (206038,
121647, 250900, and 260056), Centre of Excellence grant
2012–2017 of the Academy of Finland (251314), the Sigrid
Jusélius Foundation and the European Community’s Seventh
Framework Program, FP7/2009, under grant agreement 305608
(EURenOmics: European Consortium for High-Throughput
Research in Rare Kidney Diseases).
REFERENCES
Alvarez, S., Suazo, C., Boltansky, A., Ursu, M., Carvajal, D., Innocenti,
G., et al. (2013). Urinary exosomes as a source of kidney dysfunction
biomarker in renal transplantation. Transplant Proc. 45, 3719–3723. doi:
10.1016/j.transproceed.2013.08.079
Amabile, N., Guerin, A. P., Leroyer, A., Mallat, Z., Nguyen, C., Boddaert, J.,
et al. (2005). Circulating endothelial microparticles are associated with vascular
dysfunction in patients with end-stage renal failure. J. Am. Soc. Nephrol. 16,
3381–3388. doi: 10.1681/asn.2005050535
Anderson, H. C., Mulhall, D., and Garimella, R. (2010). Role of extracellular
membrane vesicles in the pathogenesis of various diseases, including cancer,
renal diseases, atherosclerosis, and arthritis. Lab. Invest. 90, 1549–1557. doi:
10.1038/labinvest.2010.152
Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D.
F., Mitchell, P. S., et al. (2011). Argonaute2 complexes carry a population of
circulating microRNAs independent of vesicles in human plasma. Proc. Natl.
Acad. Sci. U.S.A. 108, 5003–5008. doi: 10.1073/pnas.1019055108
Azmi, A. S., Bao, B., and Sarkar, F. H. (2013). Exosomes in cancer development,
metastasis, and drug resistance: a comprehensive review. CancerMetastasis Rev.
32, 623–642. doi: 10.1007/s10555-013-9441-9
Barutta, F., Tricarico,M., Corbelli, A., Annaratone, L., Pinach, S., Grimaldi, S., et al.
(2013). Urinary exosomal microRNAs in incipient diabetic nephropathy. PLoS
ONE 8:e73798. doi: 10.1371/journal.pone.0073798
Ben-Dov, I. Z., Tan, Y. C., Morozov, P., Wilson, P. D., Rennert, H., Blumenfeld,
J. D., et al. (2014). Urine microRNA as potential biomarkers of autosomal
dominant polycystic kidney disease progression: description of miRNA profiles
at baseline. PLoS ONE 9:e86856. doi: 10.1371/journal.pone.0086856
Biancone, L., Bruno, S., Deregibus, M. C., Tetta, C., and Camussi, G.
(2012). Therapeutic potential of mesenchymal stem cell-derived microvesicles.
Nephrol. Dial. Transplant. 27, 3037–3042. doi: 10.1093/ndt/gfs168
Blackwell, R. H., Franzen, C. A., Flanigan, R. C., Kuo, P. C., and Gupta,
G. N. (2014). The untapped potential of urine shed bladder cancer
exosomes: biomarkers, signaling, and therapeutics. Bladder 1, e7. doi:
10.14440/bladder.2014.38
Blanchard, N., Lankar, D., Faure, F., Regnault, A., Dumont, C., Raposo, G.,
et al. (2002). TCR activation of human T cells induces the production of
exosomes bearing the TCR/CD3/zeta complex. J. Immunol. 168, 3235–3241.
doi: 10.4049/jimmunol.168.7.3235
Borges, F., Reis, L., and Schor, N. (2013a). Extracellular vesicles: structure, function,
and potential clinical uses in renal diseases. Braz. J. Med. Biol. Res. 46, 824–830.
doi: 10.1590/1414-431X20132964
Borges, F. T., Melo, S. A., Ozdemir, B. C., Kato, N., Revuelta, I., Miller, C. A., et al.
(2013b). TGF-beta1-containing exosomes from injured epithelial cells activate
fibroblasts to initiate tissue regenerative responses and fibrosis. J. Am. Soc.
Nephrol. 24, 385–392. doi: 10.1681/ASN.2012101031
Boulanger, C. M., Amabile, N., Guerin, A. P., Pannier, B., Leroyer, A. S., Mallat, C.
N., et al. (2007). In vivo shear stress determines circulating levels of endothelial
microparticles in end-stage renal disease. Hypertension 49, 902–908. doi:
10.1161/01.HYP.0000259667.22309.df
Bruno, S., Grange, C., Collino, F., Deregibus, M. C., Cantaluppi, V., Biancone,
L., et al. (2012). Microvesicles derived from mesenchymal stem cells enhance
survival in a lethal model of acute kidney injury. PLoS ONE 7:e33115. doi:
10.1371/journal.pone.0033115
Bruno, S., Grange, C., Deregibus, M. C., Calogero, R. A., Saviozzi, S., Collino,
F., Morando, L., et al. (2009). Mesenchymal stem cell-derived microvesicles
protect against acute tubular injury. J. Am. Soc. Nephrol. 20, 1053–1067. doi:
10.1681/asn.2008070798
Camussi, G., Deregibus, M. C., Bruno, S., Cantaluppi, V., and Biancone, L. (2010).
Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney
Int. 78, 838–848. doi: 10.1038/ki.2010.278
Cantaluppi, V., Gatti, S., Medica, D., Figliolini, F., Bruno, S., Deregibus,
M. C., et al. (2012). Microvesicles derived from endothelial progenitor
cells protect the kidney from ischemia–reperfusion injury by microRNA-
dependent reprogramming of resident renal cells. Kidney Int. 82, 412–427. doi:
10.1038/ki.2012.105
Carayon, K., Chaoui, K., Ronzier, E., Lazar, I., Bertrand-Michel, J., Roques,
V., Balor, S., et al. (2011). Proteolipidic composition of exosomes changes
during reticulocyte maturation. J. Biol. Chem. 286, 34426–34439. doi:
10.1074/jbc.m111.257444
Chairoungdua, A., Smith, D. L., Pochard, P., Hull, M., and Caplan, M. J. (2010).
Exosome release of beta-catenin: a novel mechanism that antagonizes Wnt
signaling. J. Cell Biol. 190, 1079–1091. doi: 10.1083/jcb.201002049
Chen, G., Zhang, Y., and Wu, X. (2014a). 786-0 Renal cancer cell line-derived
exosomes promote 786-0 cell migration and invasion in vitro. Oncol. Lett. 7,
1576–1580. doi: 10.3892/ol.2014.1962
Chen, H., Lai, P., Lan, Y., Cheng, C., Zhong, W., Lin, Y., et al. (2014b).
Exosomal ATF3 RNA attenuates Pro-inflammatory gene MCP-1 transcription
in renal ischemia-reperfusion. J. Cell. Physiol. 229, 1202–1211. doi: 10.1002/
jcp.24554
Chen, L., Charrier, A., Zhou, Y., Chen, R., Yu, B., Agarwal, K., et al. (2014c).
Epigenetic regulation of connective tissue growth factor by MicroRNA-214
delivery in exosomes from mouse or human hepatic stellate cells. Hepatology
59, 1118–1129. doi: 10.1002/hep.26768
Christianson, H. C., Svensson, K. J., van Kuppevelt, T. H., Li, J. P., and Belting,
M. (2013). Cancer cell exosomes depend on cell-surface heparan sulfate
proteoglycans for their internalization and functional activity. Proc. Natl. Acad.
Sci. U.S.A. 110, 17380–17385. doi: 10.1073/pnas.1304266110
Colombo, M., Raposo, G., and Théry, C. (2014). Biogenesis, secretion, and
intercellular interactions of exosomes and other extracellular vesicles. Annu.
Rev. Cell Dev. Biol. 30, 255–289. doi: 10.1146/annurev-cellbio-101512-122326
Corbetta, S., Raimondo, F., Tedeschi, S., Syren, M. L., Rebora, P., Savoia, A., et al.
(2015). Urinary exosomes in the diagnosis of Gitelman and Bartter syndromes.
Nephrol. Dial. Transplant. 30, 621–630. doi: 10.1093/ndt/gfu362
Dear, J. W., Street, J. M., and Bailey, M. A. (2013). Urinary exosomes: a reservoir
for biomarker discovery and potential mediators of intrarenal signalling.
Proteomics 13, 1572–1580. doi: 10.1002/pmic.201200285
Demory Beckler, M., Higginbotham, J. N., Franklin, J. L., Ham, A. J., Halvey, P.
J., Imasuen, I. E., et al. (2013). Proteomic analysis of exosomes from mutant
KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol.
Cell. Proteomics 12, 343–355. doi: 10.1074/mcp.M112.022806
Denzer, K., van Eijk, M., Kleijmeer, M. J., Jakobson, E., de Groot, C., and Geuze, H.
J. (2000). Follicular dendritic cells carry MHC class II-expressing microvesicles
at their surface. J. Immunol. 165, 1259–1265. doi: 10.4049/jimmunol.165.3.1259
Frontiers in Cell and Developmental Biology | www.frontiersin.org 10 October 2015 | Volume 3 | Article 65
Krause et al. Exosomes as renal inductive signals
Diao, J., Yang, X., Song, X., Chen, S., He, Y., Wang, Q., et al. (2015). Exosomal
Hsp70mediates immunosuppressive activity of themyeloid-derived suppressor
cells via phosphorylation of Stat3. Med. Oncol. 32, 1–10. doi: 10.1007/s12032-
014-0453-2
Dimov, I., Jankovic Velickovic, L., and Stefanovic, V. (2009). Urinary exosomes.
ScientificWorldJournal 9, 1107–1118. doi: 10.1100/tsw.2009.128
Dimuccio, V., Ranghino, A., Praticò Barbato, L., Fop, F., Biancone, L., Camussi,
G., et al. (2014). Urinary CD133 extracellular vesicles are decreased in kidney
transplanted patients with slow graft function and vascular damage. PLoS ONE
9:e104490. doi: 10.1371/journal.pone.0104490
Dorronsoro, A., and Robbins, P. D. (2013). Regenerating the injured kidney with
human umbilical cordmesenchymal stem cell-derived exosomes. Stem Cell Res.
Ther. 4, 39. doi: 10.1186/scrt187
Du, T., J. G.,Wu, S., Cheng, Z., Cheng, J., and Zou, X. (2014).Microvesicles derived
from human Wharton’s jelly mesenchymal stem cells promote human renal
cancer cell growth and aggressiveness through induction of hepatocyte growth
factor. PLoS ONE9:e96836. doi: 10.1371/journal.pone.0096836
Eikmans, M., Baelde, H. J., Hagen, E. C., Paul, L. C., Eilers, P. H., De Heer, E., et al.
(2003). Renal mRNA levels as prognostic tools in kidney diseases. J. Am. Soc.
Nephrol. 14, 899–907. doi: 10.1097/01.asn.0000056611.92730.7b
Eliseeva, I., Kim, E., Guryanov, S., Ovchinnikov, L., and Lyabin, D. (2011). Y-
box-binding protein 1 (YB-1) and its functions. Biochemistry (Moscow) 76,
1402–1433. doi: 10.1134/S0006297911130049
Escola, J. M., Kleijmeer, M. J., Stoorvogel, W., Griffith, J. M., Yoshie, O., and
Geuze, H. J. (1998). Selective enrichment of tetraspan proteins on the internal
vesicles of multivesicular endosomes and on exosomes secreted by human
B-lymphocytes. J. Biol. Chem. 273, 20121–20127. doi: 10.1074/jbc.273.32.20121
Fang, D. Y., King, H. W., Li, J. Y., and Gleadle, J. M. (2013). Exosomes and the
kidney: blaming the messenger. Nephrology 18, 1–10. doi: 10.1111/nep.12005
Faure, V., Dou, L., Sabatier, F., Cerini, C., Sampol, J., Berland, Y., et al.
(2006). Elevation of circulating endothelial microparticles in patients with
chronic renal failure. J. Thromb. Haemost. 4, 566–573. doi: 10.1111/j.1538-
7836.2005.01780.x
Feng, D., Zhao, W., Ye, Y., Bai, X., Liu, R., Chang, L., et al. (2010). Cellular
internalization of exosomes occurs through phagocytosis. Traffic 11, 675–687.
doi: 10.1111/j.1600-0854.2010.01041.x
Fitzner, D., Schnaars, M., van Rossum, D., Krishnamoorthy, G., Dibaj, P., Bakhti,
M., et al. (2011). Selective transfer of exosomes from oligodendrocytes
to microglia by macropinocytosis. J. Cell. Sci. 124, 447–458. doi:
10.1242/jcs.074088
Fong, M. Y., Zhou, W., Liu, L., Alontaga, A. Y., Chandra, M., Ashby, J., et al.
(2015). Breast-cancer-secreted miR-122 reprograms glucose metabolism in
premetastatic niche to promote metastasis. Nat. Cell Biol. 17, 183–194. doi:
10.1038/ncb3094
Gatti, S., Bruno, S., Deregibus, M. C., Sordi, A., Cantaluppi, V., Tetta, C.,
et al. (2011). Microvesicles derived from human adult mesenchymal stem
cells protect against ischaemia-reperfusion-induced acute and chronic kidney
injury. Nephrol. Dial. Transplant. 26, 1474–1483. doi: 10.1093/ndt/gfr015
Gildea, J. J., Seaton, J. E., Victor, K. G., Reyes, C. M., Wang, D. B., Pettigrew,
A. C., et al. (2014). Exosomal transfer from human renal proximal tubule
cells to distal tubule and collecting duct cells. Clin. Biochem. 47, 89–94. doi:
10.1016/j.clinbiochem.2014.06.018
Gonzales, P. A., Pisitkun, T., Hoffert, J. D., Tchapyjnikov, D., Star, R. A., Kleta,
R., et al. (2009). Large-scale proteomics and phosphoproteomics of urinary
exosomes. J. Am. Soc. Nephrol. 20, 363–379. doi: 10.1681/asn.2008040406
Gonzalez-Calero, L., Martin-Lorenzo, M., and Alvarez-Llamas, G. (2014).
Exosomes: a potential key target in cardio-renal syndrome. Front. Immunol.
5:465. doi: 10.3389/fimmu.2014.00465
Grange, C., Collino, F., Tapparo, M., and Camussi, G. (2014). Oncogenic micro-
RNAs and renal cell carcinoma. Front. Oncol. 4:49. doi: 10.3389/fonc.2014.
00049
Grange, C., Tapparo, M., Collino, F., Vitillo, L., Damasco, C., Deregibus, M.
C., et al. (2011). Microvesicles released from human renal cancer stem cells
stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res.
71, 5346–5356. doi: 10.1158/0008-5472.CAN-11-0241
Greening, D. W., Gopal, S. K., Xu, R., Simpson, R. J., and Chen, W. (2015).
Exosomes and their roles in immune regulation and cancer. Semin. Cell Dev.
Biol. 40, 72–81. doi: 10.1016/j.semcdb.2015.02.009
Gu, X., Erb, U., Büchler, M. W., and Zöller, M. (2015). Improved vaccine efficacy
of tumor exosome compared to tumor lysate loaded dendritic cells in mice. Int.
J. Cancer 136, E74–E84. doi: 10.1002/ijc.29100
Hanson, P. I., and Cashikar, A. (2012). Multivesicular body morphogenesis. Annu.
Rev. Cell Dev. Biol. 28, 337–362. doi: 10.1146/annurev-cellbio-092910-154152
Henne, W. M., Stenmark, H., and Emr, S. D. (2013). Molecular mechanisms of
the membrane sculpting ESCRT pathway. Cold Spring Harb Perspect. Biol.
5:a016766. doi: 10.1101/cshperspect.a016766
Jiang, X. L., Zhang, Y., Tan, B., Luo, C. L., and Wu, X. H. (2014). Renal tumor-
derived exosomes inhibit hepaCAM expression of renal carcinoma cells in a p-
AKT-dependent manner. Neoplasma 61, 416–423. doi: 10.4149/neo_2014_051
Johnsen, K. B., Gudbergsson, J. M., Skov,M. N., Pilgaard, L., Moos, T., andDuroux,
M. (2014). A comprehensive overview of exosomes as drug delivery vehicles—
Endogenous nanocarriers for targeted cancer therapy. Biochim. Biophys. Acta
1846, 75–87. doi: 10.1016/j.bbcan.2014.04.005
Kalani, A., Mohan, A., Godbole, M. M., Bhatia, E., Gupta, A., Sharma, R.
K., et al. (2013). Wilm’s tumor-1 protein levels in urinary exosomes from
diabetic patients with or without proteinuria. PLoS ONE 8:e60177. doi:
10.1371/journal.pone.0060177
Knepper, M., and Pisitkun, T. (2007). Exosomes in urine: who would have
thought. . . ?. Kidney Int. 72, 1043–1045. doi: 10.1038/sj.ki.5002510
Koppers-Lalic, D., Hackenberg, M., Bijnsdorp, I. V., van Eijndhoven, M. A., Sadek,
P., Sie, D., et al. (2014). Nontemplated nucleotide additions distinguish the
small RNA composition in cells from exosomes. Cell Rep. 8, 1649–1658. doi:
10.1016/j.celrep.2014.08.027
Kowal, J., Tkach, M., and Thery, C. (2014). Biogenesis and secretion of exosomes.
Curr. Opin. Cell Biol. 29, 116–125. doi: 10.1016/j.ceb.2014.05.004
Krause, M., Rak-Raszewska, A., Pietilä, I., Quaggin, S. E., and Vainio,
S. (2015). Signaling during kidney development. Cells 4, 112–132. doi:
10.3390/cells4020112
Kwon, S., Liu, K. D., and Mostov, K. E. (2014). Intercellular transfer of GPRC5B
via exosomes drives HGF-mediated outward growth. Curr. Biol. 24, 199–204.
doi: 10.1016/j.cub.2013.12.010
Lee, T. H., D’Asti, E., Magnus, N., Al-Nedawi, K., Meehan, B., and Rak, J. (2011).
Microvesicles as mediators of intercellular communication in cancer—the
emerging science of cellular ‘debris’. Semin. Immunopathol. 33, 455–467. doi:
10.1007/s00281-011-0250-3
Liang, B., Peng, P., Chen, S., Li, L., Zhang, M., Cao, D., et al. (2013).
Characterization and proteomic analysis of ovarian cancer-derived exosomes.
J. Proteomics 80, 171–182. doi: 10.1016/j.jprot.2012.12.029
Lu, Q., Zhang, J., Allison, R., Gay, H., Yang, W., Bhowmick, N. A., et al. (2009).
Identification of extracellular δ-catenin accumulation for prostate cancer
detection. Prostate 69, 411–418. doi: 10.1002/pros.20902
Lv, L., Cao, Y., Pan, M., Liu, H., Tang, R., Ma, K., et al. (2014). CD2AP mRNA in
urinary exosome as biomarker of kidney disease. Clin. Chim. Acta 428, 26–31.
doi: 10.1016/j.cca.2013.10.003
Lv, L. L., Cao, Y. H., Ni, H. F., Xu, M., Liu, D., Liu, H., et al. (2013). MicroRNA-29c
in urinary exosome/microvesicle as a biomarker of renal fibrosis. Am. J. Physiol.
Renal Physiol. 305, F1220–F1227. doi: 10.1152/ajprenal.00148.2013
Mathivanan, S., and Simpson, R. J. (2009). ExoCarta: a compendium of
exosomal proteins and RNA. Proteomics 9, 4997–5000. doi: 10.1002/pmic.2009
00351
Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J.,
et al. (2015). Glypican-1 identifies cancer exosomes and detects early pancreatic
cancer. Nature 523, 177–182. doi: 10.1038/nature14581
Minciacchi, V. R., Freeman, M. R., and Di Vizio, D. (2015). Extracellular vesicles
in cancer: exosomes, microvesicles and the emerging role of large oncosomes.
Semin. Cell Dev. Biol. 40, 41–51. doi: 10.1016/j.semcdb.2015.02.010
Miranda, K. C., Bond, D. T., McKee, M., Skog, J., Pãunescu, T. G., Da Silva, N.,
et al. (2010). Nucleic acids within urinary exosomes/microvesicles are potential
biomarkers for renal disease. Kidney Int. 78, 191–199. doi: 10.1038/ki.2010.106
Mitchell, P. J., Welton, J., Staffurth, J., Mason, M. D., Tabi, Z., and Clayton, A.
(2009). Can urinary exosomes act as treatment response markers in prostate
cancer. J. Transl. Med. 7:4. doi: 10.1186/1479-5876-7-4
Mittelbrunn, M., Gutiérrez-Vázquez, C., Villarroya-Beltri, C., González, S.,
Sánchez-Cabo, F., González, M. Á., et al. (2011). Unidirectional transfer of
microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat.
Commun. 2:282. doi: 10.1038/ncomms1285
Frontiers in Cell and Developmental Biology | www.frontiersin.org 11 October 2015 | Volume 3 | Article 65
Krause et al. Exosomes as renal inductive signals
Montecalvo, A., Larregina, A. T., Shufesky, W. J., Stolz, D. B., Sullivan, M. L.,
Karlsson, J. M., Baty, C. J., et al. (2012). Mechanism of transfer of functional
microRNAs between mouse dendritic cells via exosomes. Blood 119, 756–766.
doi: 10.1182/blood-2011-02-338004
Morelli, A. E., Larregina, A. T., Shufesky, W. J., Sullivan, M. L., Stolz, D. B.,
Papworth, G. D., Zahorchak, A. F., et al. (2004). Endocytosis, intracellular
sorting, and processing of exosomes by dendritic cells. Blood 104, 3257–3266.
doi: 10.1182/blood-2004-03-0824
Mulcahy, L. A., Pink, R. C., and Carter, D. R. F. (2014). Routes and mechanisms
of extracellular vesicle uptake. J. Extracell. Vesicles 3:24641. doi: 10.3402/jev.v3.
24641
Musante, L., Tataruch, D. E., and Holthofer, H. (2014). Use and isolation of urinary
exosomes as biomarkers for diabetic nephropathy. Front. Endocrinol. 5:149. doi:
10.3389/fendo.2014.00149
Nagasawa, M., Koide, H., Ohsawa, K., and Hoshi, T. (1992). Purification
of bursh border membrane vesicles from rat renal cortex by size-
exclusion chromatography. Anal. Biochem. 201, 301–305. doi: 10.1016/0003-
2697(92)90342-5
Neal, C. S., Michael, M. Z., Pimlott, L. K., Yong, T. Y., Li, J. Y., and Gleadle, J. M.
(2011). Circulating microRNA expression is reduced in chronic kidney disease.
Nephrol. Dial. Transplant. 26, 3794–3802. doi: 10.1093/ndt/gfr485
Nieto, M. A. (2011). The ins and outs of the epithelial to mesenchymal
transition in health and disease. Annu. Rev. Cell Dev. Biol. 27, 347–376. doi:
10.1146/annurev-cellbio-092910-154036
Nolte-’t Hoen, E. N., Buschow, S. I., Anderton, S. M., Stoorvogel, W., andWauben,
M. H. (2009). Activated T cells recruit exosomes secreted by dendritic cells via
LFA-1. Blood 113, 1977–1981. doi: 10.1182/blood-2008-08-174094
Pan, B., and Johnstone, R. M. (1983). Fate of the transferrin receptor during
maturation of sheep reticulocytes in vitro: selective externalization of the
receptor. Cell 33, 967–978. doi: 10.1016/0092-8674(83)90040-5
Parolini, I., Federici, C., Raggi, C., Lugini, L., Palleschi, S., De Milito, A.,
Coscia, C., et al. (2009). Microenvironmental pH is a key factor for exosome
traffic in tumor cells. J. Biol. Chem. 284, 34211–34222. doi: 10.1074/jbc.m109.
041152
Pegtel, D. M., Cosmopoulos, K., Thorley-Lawson, D. A., van Eijndhoven, M.
A., Hopmans, E. S., Lindenberg, J. L., et al. (2010). Functional delivery of
viral miRNAs via exosomes. Proc. Natl. Acad. Sci. U.S.A. 107, 6328–6333. doi:
10.1073/pnas.0914843107
Peinado, H., Aleèkoviæ, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-
Bueno, G., et al. (2012). Melanoma exosomes educate bone marrow progenitor
cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891.
doi: 10.1038/nm.2753
Pisitkun, T., Shen, R. F., and Knepper, M. A. (2004). Identification and proteomic
profiling of exosomes in human urine. Proc. Natl. Acad. Sci. U.S.A. 101,
13368–13373. doi: 10.1073/pnas.0403453101
Properzi, F., Logozzi, M., and Fais, S. (2013). Exosomes: the future of biomarkers
in medicine. Biomark. Med. 7, 769–778. doi: 10.2217/bmm.13.63
Rana, S., Yue, S., Stadel, D., and Zöller, M. (2012). Toward tailored exosomes: the
exosomal tetraspanin web contributes to target cell selection. Int. J. Biochem.
Cell Biol. 44, 1574–1584. doi: 10.1016/j.biocel.2012.06.018
Ranghino, A., Dimuccio, V., Papadimitriou, E., and Bussolati, B. (2014).
Extracellular vesicles in the urine: markers and mediators of tissue damage and
regeneration. Clin. Kidney J. 8, 23–30. doi: 10.1093/ckj/sfu136
Raposo, G., and Stoorvogel, W. (2013). Extracellular vesicles: exosomes,
microvesicles, and friends. J. Cell Biol. 200, 373–383. doi: 10.1083/jcb.2012
11138
Raposo, G., Tenza, D., Mecheri, S., Peronet, R., Bonnerot, C., and Desaymard, C.
(1997). Accumulation of major histocompatibility complex class II molecules
in mast cell secretory granules and their release upon degranulation. Mol. Biol.
Cell 8, 2631–2645. doi: 10.1091/mbc.8.12.2631
Reinhardt, T. A., Sacco, R. E., Nonnecke, B. J., and Lippolis, J. D. (2013).
Bovine milk proteome: quantitative changes in normal milk exosomes, milk fat
globule membranes and whey proteomes resulting from Staphylococcus aureus
mastitis. J. Proteomics 82, 141–154. doi: 10.1016/j.jprot.2013.02.013
Reis, L. A., Borges, F. T., Simoes, M. J., Borges, A. A., Sinigaglia-Coimbra, R.,
and Schor, N. (2012). Bone marrow-derived mesenchymal stem cells repaired
but did not prevent gentamicin-induced acute kidney injury through paracrine
effects in rats. PLoS ONE 7:e44092. doi: 10.1371/journal.pone.0044092
Salih, M., Zietse, R., and Hoorn, E. J. (2014). Urinary extracellular vesicles
and the kidney: biomarkers and beyond. Am. J. Physiol. Renal Physiol. 306,
F1251–F1259. doi: 10.1152/ajprenal.00128.2014
Skog, J., Würdinger, T., van Rijn, S., Meijer, D. H., Gainche, L., Curry, W. T.,
et al. (2008). Glioblastoma microvesicles transport RNA and proteins that
promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10,
1470–1476. doi: 10.1038/ncb1800
Skogberg, G., Gudmundsdottir, J., van der Post, S., Sandström, K., Bruhn, S.,
Benson, M., et al. (2013). Characterization of human thymic exosomes. PLoS
ONE 8:e67554. doi: 10.1371/journal.pone.0067554
Smalley, D. M., Sheman, N. E., Nelson, K., and Theodorescu, D. (2008). Isolation
and identification of potential urinary microparticle biomarkers of bladder
cancer. J. Proteome Res. 7, 2088–2096. doi: 10.1021/pr700775x
Stoorvogel, W., Kleijmeer, M. J., Geuze, H. J., and Raposo, G. (2002). The
biogenesis and functions of exosomes. Traffic 3, 321–330. doi: 10.1034/j.1600-
0854.2002.30502.x
Stoorvogel, W. (2012). Functional transfer of microRNA by exosomes. Blood 119,
646–648. doi: 10.1182/blood-2011-11-389478
Street, J. M., Birkhoff, W., Menzies, R. I., Webb, D. J., Bailey, M. A.,
and Dear, J. W. (2011). Exosomal transmission of functional aquaporin
2 in kidney cortical collecting duct cells. J. Physiol. 589, 6119–6127. doi:
10.1113/jphysiol.2011.220277
Suntres, Z. E., Smith, M. G., Momen-Heravi, F., Hu, J., Zhang, X., Wu, Y., et al.
(2013). Therapeutic uses of exosomes. Exosomes Microvesicles 1, 1–8. doi:
10.5772/56522
Svensson, K. J., Christianson, H. C., Wittrup, A., Bourseau-Guilmain, E.,
Lindqvist, E., Svensson, L. M., et al. (2013). Exosome uptake depends on
ERK1/2-heat shock protein 27 signaling and lipid Raft-mediated endocytosis
negatively regulated by caveolin-1. J. Biol. Chem. 288, 17713–17724. doi:
10.1074/jbc.m112.445403
Tang, F., Kaneda, M., O’Carroll, D., Hajkova, P., Barton, S. C., Sun, Y. A., et al.
(2007). Maternal microRNAs are essential for mouse zygotic development.
Genes Dev. 21, 644–648. doi: 10.1101/gad.418707
Tauro, B. J., Mathias, R. A., Greening, D. W., Gopal, S. K., Ji, H., Kapp, E.
A., Coleman, B. M., et al. (2013). Oncogenic H-ras reprograms Madin-
Darby canine kidney (MDCK) cell-derived exosomal proteins following
epithelial-mesenchymal transition. Mol. Cell. Proteomics 12, 2148–2159. doi:
10.1074/mcp.m112.027086
Théry, C., Ostrowski, M., and Segura, E. (2009). Membrane vesicles as conveyors
of immune responses. Nat. Rev. Immunol. 9, 581–593. doi: 10.1038/nri2567
Théry, C., Zitvogel, L., and Amigorena, S. (2002). Exosomes: composition,
biogenesis and function. Nat. Rev. Immunol. 2, 569–579. doi: 10.1038/nri855
Tian, T., Zhu, Y. L., Zhou, Y. Y., Liang, G. F., Wang, Y. Y., Hu, F. H., et al. (2014).
Exosome uptake through clathrin-mediated endocytosis and macropinocytosis
and mediating miR-21 delivery. J. Biol. Chem. 289, 22258–22267. doi:
10.1074/jbc.m114.588046
Tomasoni, S., Longaretti, L., Rota, C., Morigi, M., Conti, S., Gotti, E., et al.
(2012). Transfer of growth factor receptor mRNA via exosomes unravels the
regenerative effect of mesenchymal stem cells. Stem Cells Dev. 22, 772–780. doi:
10.1089/scd.2012.0266
Urbanelli, L., Magini, A., Buratta, S., Brozzi, A., Sagini, K., Polchi, A., et al.
(2013). Signaling pathways in exosomes biogenesis, secretion and fate. Genes
4, 152–170. doi: 10.3390/genes4020152
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., and Lötvall, J. O.
(2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel
mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659. doi:
10.1038/ncb1596
van Balkom, B. W., Pisitkun, T., Verhaar, M. C., and Knepper, M. A. (2011).
Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases.
Kidney Int. 80, 1138–1145. doi: 10.1038/ki.2011.292
van Koppen, A., Joles, J. A., Van Balkom, B., Lim, S. K., de Kleijn, D., Giles, R. H.,
et al. (2012). Human embryonic mesenchymal stem cell-derived conditioned
medium rescues kidney function in rats with established chronic kidney
disease. PLoS ONE 7:e38746. doi: 10.1371/journal.pone.0038746
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., and Remaley,
A. T. (2011). MicroRNAs are transported in plasma and delivered to recipient
cells by high-density lipoproteins. Nat. Cell Biol. 13, 423–433. doi: 10.1038/
ncb2210
Frontiers in Cell and Developmental Biology | www.frontiersin.org 12 October 2015 | Volume 3 | Article 65
Krause et al. Exosomes as renal inductive signals
Vishnubhatla, I., Corteling, R., Stevanato, L., Hicks, C., and Sinden, J. (2014).
The development of stem cell–derived exosomes as a cell-free regenerative
medicine. J. Circ. Biomark 143, 2. doi: 10.5772/58597
Wels, J., Kaplan, R. N., Rafii, S., and Lyden, D. (2008). Migratory neighbors and
distant invaders: tumor-associated niche cells. Genes Dev. 22, 559–574. doi:
10.1101/gad.1636908
White, I. J., Bailey, L. M., Aghakhani, M. R., Moss, S. E., and Futter, C. E. (2006).
EGF stimulates annexin 1-dependent inward vesiculation in a multivesicular
endosome subpopulation. EMBO J. 25, 1–12. doi: 10.1038/sj.emboj.7600759
Yanez-Mo, M., Siljander, P. R., Andreu, Z., Zavec, A. B., Borras, F. E., Buzas, E. I.,
Buzas, K., et al. (2015). Biological properties of extracellular vesicles and their
physiological functions. J. Extracell Vesicles 4:27066. doi: 10.3402/jev.v4.27066
Yang, L., Wu, X., Wang, D., Luo, C., and Chen, L. (2013). Renal carcinoma cell-
derived exosomes induce human immortalized line of Jurkat T lymphocyte
apoptosis in vitro. Urol. Int. 91, 363–369. doi: 10.1159/000348747
Zhang, B., Wang, M., Gong, A., Zhang, X., Wu, X., Zhu, Y., et al. (2015a).
HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound
healing. Stem Cells 33, 2158–2168. doi: 10.1002/stem.1771
Zhang, J., Li, S., Li, L., Li, M., Guo, C., Yao, J., et al. (2015b). Exosome and
exosomal microRNA: trafficking, sorting, and function. Genomics Proteomics
Bioinformatics 13, 17–24. doi: 10.1016/j.gpb.2015.02.001
Zhang, L., Wu, X., Luo, C., Chen, X., Yang, L., Tao, J., et al. (2013). The 786-0
renal cancer cell-derived exosomes promote angiogenesis by downregulating
the expression of hepatocyte cell adhesionmolecule. Mol. Med. Rep. 8, 272–276.
doi: 10.3892/mmr.2013.1458
Zhang, Y., Luo, C., He, B., Zhang, J., Cheng, G., Wu, X., et al. (2010). Exosomes
derived from IL-12-anchored renal cancer cells increase induction of specific
antitumor response in vitro: a novel vaccine for renal cell carcinoma. Int. J.
Oncol. 36, 133–140. doi: 10.3892/ijo_00000484
Zhou, H., Cheruvanky, A., Hu, X., Matsumoto, T., Hiramatsu, N., Cho, M. E., et al.
(2008). Urinary exosomal transcription factors, a new class of biomarkers for
renal disease. Kidney Int. 74, 613–621. doi: 10.1038/ki.2008.206
Zhou, H., Kajiyama, H., Tsuji, T., Hu, X., Leelahavanichkul, A., Vento, S., Frank,
R., et al. (2013b). Urinary exosomal Wilms’ tumor-1 as a potential biomarker
for podocyte injury. Am. J. Physiol. Renal Physiol. 305, F553–F559. doi:
10.1152/ajprenal.00056.2013
Zhou, H., Pisitkun, T., Aponte, A., Yuen, P. S., Hoffert, J. D., Yasuda, H.,
et al. (2006). Exosomal Fetuin-A identified by proteomics: a novel urinary
biomarker for detecting acute kidney injury. Kidney Int. 70, 1847–1857. doi:
10.1038/sj.ki.5001874
Zhou, Y., Xu, H., Xu, W., Wang, B., Wu, H., Tao, Y., et al. (2013a). Exosomes
released by human umbilical cord mesenchymal stem cells protect against
cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem
Cell Res. Ther. 4, 34. doi: 10.1186/scrt194
Zitvogel, L., Regnault, A., Lozier, A., Wolfers, J., Flament, C., Tenza, D.,
et al. (1998). Eradication of established murine tumors using a novel cell-
free vaccine: dendritic cell derived exosomes. Nat. Med. 4, 594–600. doi:
10.1038/nm0598-594
Zubiri, I., Posada-Ayala, M., Sanz-Maroto, A., Calvo, E., Martin-Lorenzo, M.,
Gonzalez-Calero, L., et al. (2014). Diabetic nephropathy induces changes
in the proteome of human urinary exosomes as revealed by label-free
comparative analysis. J. Proteomics 96, 92–102. doi: 10.1016/j.jprot.2013.
10.037
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Krause, Samoylenko and Vainio. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 13 October 2015 | Volume 3 | Article 65
